Fundz

Vergent Bioscience reported raising $18.7 Million in an initial SEC Form D filing, from an offering of $32 Million

PRIVATEOct 20, 2025

Amount Raised

$18.7 Million

$18.7 Million sold, per SEC Form D (first sale Oct 7, 2025)

Round Type

Venture

MinneapolisBiotechnologyHealth CareTherapeutics

Who to call at Vergent Bioscience, and when

A new round usually means Vergent Bioscience is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Vergent Bioscience raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Vergent Bioscience, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Vergent Bioscience

Location

5810 W 78TH ST

Minneapolis, Minnesota, United States

About

Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors. Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We are first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors. Our approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Vergent Bioscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsJohn S., Executive Officer, Director hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Vergent Bioscience's next move

See what Strategic adds

Vergent Bioscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.